Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) – Pipeline Review, H2 2016’, provides in depth analysis on Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) targeted pipeline therapeutics.

The report provides comprehensive information on the Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46)

The report reviews Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) targeted therapeutics and enlists all their major and minor projects

The report assesses Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Amgen Inc.

AstraZeneca Plc

Bristol-Myers Squibb Company

Eisai Co., Ltd.

Eli Lilly and Company

Genentech, Inc.

Johnson & Johnson

Merck & Co., Inc.

Novartis AG

Vitae Pharmaceuticals, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC

3.4.23.46) Overview 8

Therapeutics Development 9

Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC

3.4.23.46) - Products under Development by Stage of Development 9

Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC

3.4.23.46) - Products under Development by Therapy Area 10

Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC

3.4.23.46) - Products under Development by Indication 11

Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC

3.4.23.46) - Pipeline Products Glance 12

Late Stage Products 12

Early Stage Products 13

Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC

3.4.23.46) - Products under Development by Companies 14

Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC

3.4.23.46) - Products under Development by Universities/Institutes 16

Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC

3.4.23.46) - Therapeutics Assessment 18

Assessment by Monotherapy/Combination Products 18

Assessment by Mechanism of Action 19

Assessment by Route of Administration 20

Assessment by Molecule Type 21

Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC

3.4.23.46) - Companies Involved in Therapeutics Development 23

Amgen Inc. 23

AstraZeneca Plc 24

Bristol-Myers Squibb Company 25

Eisai Co., Ltd. 26

Eli Lilly and Company 27

Genentech, Inc. 28

Johnson & Johnson 29

Merck & Co., Inc. 30

Novartis AG 31

Vitae Pharmaceuticals, Inc. 32

Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC

3.4.23.46) - Drug Profiles 33

AMG-8718 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

AVCRI-104P3 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

AVCRI-175P1 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

AZ-4217 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

AZD-3293 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

CNP-520 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

E-2609 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

ER-901356 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

GNE-892 - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

JNJ-54861911 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

LY-2811376 + LY-3002813 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

LY-3202626 - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

Oligonucleotides to Activate miR-188-3p for Alzheimer's Disease - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

Small Molecule to Inhibit APP-Selective BACE Enzyme for Alzheimer's Disease - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

Small Molecule to Inhibit BACE 1 for Alzheimer’s Disease - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

Small Molecule to Inhibit BACE1 for Alzheimer's Disease - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

Small Molecule to Inhibit BACE1 for Alzheimer’s Disease - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

Small Molecules to Inhibit BACE1 for Alzheimer Disease - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

Small Molecules to Inhibit Beta Secretase 1 for Alzheimer's Disease - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

TAK-070 - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

verubecestat - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

VTP-36951 - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC

3.4.23.46) - Dormant Projects 59

Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC

3.4.23.46) - Discontinued Products 60

Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC

3.4.23.46) - Featured News & Press Releases 61

Jun 14, 2016: New Alzheimer’s Study Aimed at Preventing or Delaying Symptoms 61

Apr 08, 2016: AstraZeneca and Eli Lilly and Company announce continuation of pivotal clinical trial for people with early Alzheimer’s disease 62

Jan 28, 2016: Merck Completes Enrollment in Pivotal Phase 3 “EPOCH” Trial Investigating the Efficacy and Safety of Verubecestat in Patients with Mild-to-Moderate Alzheimer’s Disease 63

Dec 01, 2014: AstraZeneca and Eli Lilly and Company initiate pivotal clinical trial for patients with early Alzheimer’s disease 63

May 07, 2014: AstraZeneca In Discussions For Partnership To Develop Alzheimer's Drug 64

Dec 10, 2013: Merck Advances Development Program for Investigational Alzheimer’s Disease Therapy, MK-8931 64

Jul 14, 2013: Merck Presents Findings from Phase 1b Study of Investigational BACE Inhibitor, MK-8931, in Patients with Alzheimer’s Disease 65

Apr 24, 2013: GE Healthcare And Eisai To Partner On Alzheimer's Disease Research 66

Dec 03, 2012: Merck Initiates Phase II/III Study of Investigational BACE Inhibitor MK-8931 For Treatment Of Alzheimer's Disease 67

Jul 19, 2012: Eisai Presents First Clinical Data For BACE Inhibitor E2609 At AAIC 2012 67

Jul 13, 2012: Eisai To Present First Clinical Data For Bace Inhibitor E2609 At Alzheimer's Association International Conference 2012 68

Jun 08, 2012: Takeda Announces Transfer Of TAK-070 To National University Corporation 69

Apr 27, 2012: Merck Presents Results Of Phase I Clinical Trial Evaluating Investigational BACE Inhibitor MK-8931 At American Academy Of Neurology 70

Feb 09, 2009: Ligand Earns $1 Million Milestone Payment On Progress Of Drug Candidate For Alzheimer's Disease 70

Appendix 72

Methodology 72

Coverage 72

Secondary Research 72

Primary Research 72

Expert Panel Validation 72

Contact Us 72

Disclaimer 73

List of Tables

List of Tables

Number of Products under Development for, H2 2016 9

Number of Products under Development by Therapy Area, H2 2016 10

Number of Products under Development by Indication, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Number of Products under Development by Companies, H2 2016 14

Products under Development by Companies, H2 2016 15

Number of Products under Investigation by Universities/Institutes, H2 2016 16

Products under Investigation by Universities/Institutes, H2 2016 17

Assessment by Monotherapy/Combination Products, H2 2016 18

Number of Products by Stage and Mechanism of Action, H2 2016 19

Number of Products by Stage and Route of Administration, H2 2016 20

Number of Products by Stage and Molecule Type, H2 2016 22

Pipeline by Amgen Inc., H2 2016 23

Pipeline by AstraZeneca Plc, H2 2016 24

Pipeline by Bristol-Myers Squibb Company, H2 2016 25

Pipeline by Eisai Co., Ltd., H2 2016 26

Pipeline by Eli Lilly and Company, H2 2016 27

Pipeline by Genentech, Inc., H2 2016 28

Pipeline by Johnson & Johnson, H2 2016 29

Pipeline by Merck & Co., Inc., H2 2016 30

Pipeline by Novartis AG, H2 2016 31

Pipeline by Vitae Pharmaceuticals, Inc., H2 2016 32

Dormant Projects, H2 2016 59

Discontinued Products, H2 2016 60

List of Figures

List of Figures

Number of Products under Development for, H2 2016 9

Number of Products under Development by Indication, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy/Combination Products, H2 2016 18

Number of Products by Stage and Mechanism of Actions, H2 2016 19

Number of Products by Stage and Routes of Administration, H2 2016 20

Number of Products by Molecule Types, H2 2016 21

Number of Products by Stage and Molecule Type, H2 2016 21

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports